Home 5 People 5 Michael Cottler

Michael Cottler

Partner

mcottler@geminilaw.com

Language

English

Bar Admissions

New York

Admissions

United States Patent and Trademark Office

Michael Cottler joined Gemini Law as a partner in 2023. Michael has over 17 years of experience handling and managing IP litigation and strategy in the pharmaceutical and biotech sector.

Michael brings a unique commercial perspective to Gemini. Previously, Michael was Global Head of Litigation at Alvotech, a multinational biopharmaceutical company focused on the development and manufacture of biosimilars for global markets. There he directed the company’s global prelitigation, litigation, and dispute resolution strategy, including BPCIA litigation, as well as advising on legal risk and strategy associated with global supply chain and market entry. He also gained deep knowledge concerning the development, manufacture, regulatory approval, and commercialization of biologics.

Prior to Alvotech, Michael was a partner at Goodwin Procter, where he focused on the life sciences sector and oversaw all aspects of patent litigation, from prelitigation strategy through trial and appeal, as well as contract dispute resolution.

He has published and spoken extensively regarding biotech/pharma patent litigation. While at Goodwin, he was also a Senior Editor of the firm’s treatise, Guide to Guide to Biosimilars Litigation and Regulation in the U.S. (published by Thomson-Reuters).

Michael holds a bachelor’s degree in Biologics Sciences (with a neuroscience focus) from Cornell University.

Speaking Engagements

Second Use Patents and Skinny Label, Pharma & Biotech Patent Litigation Europe (Amsterdam), January 2024
Overview of Key Legal Developments Impacting the Pharmaceutical Industry, Managing IP’s 11th Annual Intellectual Property and Innovation Summit (NYC), September 2023
Will Skinny Labelling Work for Biosimilars?, 14th Summit on Biosimilars & Innovator Biologics (Boston), June 2023
Biologics Patent Litigation: Biosimilars Launch, Preliminary Injunction Relief and Section 112, Pharma & Biotech Patent Litigation Europe (Amsterdam), January 2023
Litigation Strategy, IAM Connect: Patent Policy and Litigation USA (remote), November 2022
An In-House Perspective on Managing Outside Counsel, NYIPLA CLE (NYC), November 2022
Patent Eligibility and the Life Sciences Industry – What Next?, IPWatchdog Life Sciences Masters (Ashburn, VA), October 2022
Ethics Discussion, 14th Summit on Biosimilars & Innovator Biologics (Boston), June 2022
Overview of Key Legal Developments Impacting the Pharmaceutical Industry, Managing IP’s 10th annual Intellectual Property and Innovation Summit (New York City), May 2022
Biologics and Biosimilars, Pharma & Biotech Patent Litigation Europe (Amsterdam), March 2022

Education

J.D., Albany Law School (Union University), Magna Cum Laude, 2006
B.S., Biological Sciences, Cornell University, 2002

Bar admissions and qualifications

Michael is admitted to practice in New York, as well as before the U.S. District Court for the Southern and Eastern Districts of New York, the U.S. Court of Appeals for the Federal Circuit, and the United States Patent and Trademark Office.

Senior Editor of Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., 2020-2021 ed.
Senior Editor of Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed.
Biosimilar Patent Litigation May Be On The Rise In 2020, Law360, 2020
Union Of Tech, Life Sciences And Health Care Is Here To Stay, Law360, 2019
Turning Tide On Diagnostic Method Claims, Intellectual Property Magazine, 2018
The CAFC Split Non-Precedential Decision In Exergen v. Kaz Raises Interesting Issues About Eligibility Determinations, IPWatchdog, 2018
Does Indication-Specific Pricing Fit Generics With Carveouts?, Law360, 2017
The Ongoing Debate About Disclosing Manufacturing Process Information In The Patent Dance, Bloomberg Law: Pharmaceutical & Life Sciences News, 2018